20 October 2023 in International Journal of Antimicrobial Agents
17 October 2019 in BioMed Research International
JNJoseph Kang’eThe Nganga
DKDaniel Wainaina Kariuki
FMFrancis Wamakima Muregi
Malaria is the eighth highest contributor to global disease burden with 212 million cases and 429,000 deaths reported in 2015. There is an urgent need to develop multiple target drug to curb growing resistance by Plasmodia due to use of single target drugs and lack of vaccines. Based on a previous study, 3-chloro-4-(4-chlorophenoxy) aniline (ANI) inhibits Plasmodia enoyl acyl carrier protein reductase. This study aimed at evaluating the antiplasmodial activity of ANI combinations with artesunate (AS) or chloroquine (CQ) against P. falciparum in vitro based on the semiautomated microdilution assay and P. berghei in vivo based on Peters’ 4-day test. Data were analysed by linear regression using version 5.5 of Statistica, 2000. From the results, on the one hand, a combination of 1.1 ng/ml AS and 3.3 μg/ml of ANI inhibited 50% growth of W2, while a combination of 0.8 ng/ml of AS and 2.6 μg/ml of ANI inhibited 50% growth of 3D7. On the other hand, a combination of 22 ng/ml CQ and 3.7 μg/ml of ANI inhibited 50% growth of W2, while a combination of 4.6 ng/ml CQ and 3.1 μg/ml of ANI inhibited 50% growth of 3D7. In in vivo assays, a combination of ED50 concentrations of AS and ANI cleared all parasites, while and ED50 combinations inhibited 67.0% and 35.4% parasite growth, respectively. ED50 combinations of CQ and ANI inhibited 81.0% growth of parasites, while and ED50 combinations inhibited 27.3% and 10.2% parasite growth. Assuming a linear relationship between percentage chemosuppression and combination ratios, only 0.88 mg/kg of AS combined with 1.68 mg/kg of ANI or 1.78 mg/kg of CQ with 3.15 mg/kg of ANI inhibited 50% parasite growth in vivo. ANI combinations with AS or CQ are thus potential antimalarial drug combinations if their clinical efficacy and safety are ascertained.
1 January 2026 in Biochemistry Research International
Despite the urgent need for new therapies to treat multidrug‐resistant virulent Plasmodium falciparum , many promising antimalarial candidates fail to progress to clinical use because their pharmacokinetic (PK) profile is poorly characterized. This study predicted the PK profile of a new compound, 3‐chloro‐4‐(4‐chlorophenoxy)aniline (ANI), in silico using the pkCSM online platform. In vitro cytotoxicity in Vero E6 cells and antiplasmodial activity against chloroquine‐sensitive ( P. falciparum 3D7) and chloroquine‐resistant ( P. falciparum W2) strains were screened using the MTT colorimetric and the [ 3 H]‐hypoxanthine incorporation assays, respectively. In vivo antimalarial efficacy was evaluated in Plasmodium berghei ANKA and piperaquine‐resistant (PQ R ) P. berghei parasites in mouse models employing early and established infection tests. In silico predictions show that ANI is a substrate for CYP 3A4 and CYP 2D6 and is unlikely to inhibit the hERG potassium ion channel. ANI exhibited low cytotoxicity, with a CC 50 value of 7.90 × 10 2 ± 86.40 μM, and potent antiplasmodial activity, with IC 50 values of 1.72 ± 0.09 μM and 1.84 ± 0.21 μM against the 3D7 and W2 strains, respectively. The selectivity index of greater than 400 indicates that ANI has a broad safety margin. In vivo, ANI demonstrated antimalarial efficacy with ED 50 values of 3.07 mg/kg/day against P. berghei ANKA and 2.81 mg/kg/day against PQ R P. berghei parasites. Notably, mice treated with ANI in the established infection model survived for up to 30 days without observable adverse effects. These findings highlight ANI as a potential antimalarial compound and support further drug evaluation and development.
1 January 2026 in Journal of Parasitology Research
Malaria remains a major global health problem, with uneven progress and the greatest disease burden clustered in sub‐Saharan Africa. Antimalarial drug resistance continues to undermine malaria control efforts, with widespread resistance reported in Plasmodium falciparum, including reduced susceptibility to artemisinin‐based combination therapies (ACTs). However, despite increasing concerns over the long‐term effectiveness of ACTs, the processes through which resistance to artemether–lumefantrine (AL) partner drugs evolves and contributes to resistance against individual drug components remain poorly understood. Consequently, we investigated AL resistance in Plasmodium berghei ANKA towards understanding resistance development to full ACT regimens rather than individual drugs. Firstly, drug efficacy was evaluated using the standard 4‐day suppressive test (4‐DT), with baseline effective doses (ED 50 and ED 90 ) for the parental line determined as 1.45 and 2.80 mg/kg, respectively. Following 20 stepwise in vivo drug selection pressure passages, from the parental (0th) to the 20th passage in mice over 26 weeks, resistance increased by 2.85‐fold in ED 50 and 2.65‐fold increase in ED 90 , indicating reduced drug susceptibility and stepwise resistance selection. After five drug‐free passages and recovery following 45 days of cryopreservation at −80°C, the parasite retained slight resistance across all assays, indicating a stable resistance phenotype. In conclusion, continuous drug exposure successfully led to the development of P. berghei parasites with reduced sensitivity to AL, as evidenced by significantly lower chemo‐suppression in resistant lines compared with sensitive controls ( p < 0.05). These findings demonstrate that AL resistance can be progressively selected over a period of time and stability maintained in P. berghei , providing insights into the durability and evolutionary vulnerability of ACTs under sustained drug pressure. Future studies should enhance the level of resistance, evaluate its stability, and investigate the molecular basis of AL resistance to identify reliable genetic markers for monitoring resistance to ACTs.